A Phase 3 interventional study of Aceclidine+Brimonidine combination ophthalmic solution and Aceclidine ophthalmic solution in Presbyopia, Refractive Error and Eye Diseases, sponsored by LENZ Therapeutics, Inc. Completed at 25 sites in United States. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by LENZ Therapeutics, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Presbyopia with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Presbyopia · United States.
Among the 131 studies in Presbyopia with a site in United States, this one is the 7th largest by enrollment of the 120 interventional ones that give a count, is one of 19 that started in 2022, is one of 20 in phase 3, and was the 92nd registered.
336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.
Browse Presbyopia studies →8 of the 131 studies in Presbyopia with a site in United States are open now. Recruiting first, the newest first:
Gordon Schanzlin New Vision · Sites in United States
Ages 40+ · Healthy volunteers
Southern College of Optometry · Sites in United States
Ages 18–40 · Healthy volunteers
Southern College of Optometry · Sites in United States
Ages 45–64
VIS, Inc. · Sites in United States
Ages 40+
Bausch & Lomb Incorporated · Sites in United States
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Presbyopia studies recruiting now, 7 (39%) set no upper age limit and 9 (50%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 45 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 20 · Phase 4 8
First in 2003; this study’s year is marked. 19 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 469 is above the median of 61 across 276 interventional studies indexed under Presbyopia.
Median enrollment 75 across the 120 interventional studies, 46 across the 11 observational. Of the 113 that completed or were terminated, 84 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 131 have an industry lead sponsor. The 10 most frequent:
LENZ Therapeutics, Inc is the lead sponsor of 8 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
LENZ Therapeutics, Inc has 8 studies filed under Presbyopia — fewer than ten, so there is no comparison to draw.
4 of the studies in Presbyopia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06487897Phase 3VIS, Inc.Phase III Presbyopia Correction Using the VIS Opti-K™ System | 2026-12 |
| NCT07638943Gordon Schanzlin New VisionRefitting Satisfied INFUSE One-Day Multifocal Wearers to DAILIES TOTAL1 Multifocal Contact Lenses | 2027-01-31 |
| NCT07860567Dr. Daniel H. Chang, MDClinical Evaluation of Visual Performance, Spectacle Independence, and Patient Satisfaction With TECNIS PureSee Mini-Monovision and TECNIS PureSee-TECNIS Odyssey Mix-Match | 2027-03-01 |
| NCT06060041Bausch & Lomb IncorporatedIC-8 Apthera IOL New Enrollment Post Approval Study | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 131 studies in Presbyopia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 for the treatment of Presbyopia.
Phase 3 study to evaluate the safety and effectiveness of LNZ101 compared with LNZ100 and Brimonidine for the treatment of Presbyopia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects must not:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LNZ101 (Aceclidine /Brimonidine) ophthalmic solution
Drug: Aceclidine+Brimonidine combination ophthalmic solution
LNZ100 (Aceclidine) ophthalmic solution
Drug: Aceclidine ophthalmic solution
Brimonidine ophthalmic solution
Drug: Brimonidine
Drug pages: Aceclidine · Brimonidine
LNZ101 (Aceclidine/Brimonidine) ophthalmic solution
Also known as: LNZ101
LNZ100 Aceclidine ophthalmic solution
Also known as: LNZ100
Brimonidine ophthalmic solution
Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision
Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision on Day 1
Time frame: 3 hours post-treatment in the study eye on Day 1
| Milestone | Aceclidine + Brimonidine (LNZ101) | Aceclidine Ophthalmic Solution (LNZ100) | Brimonidine Ophthalmic Solution |
|---|---|---|---|
| Started | 156 | 157 | 156 |
| Completed | 144 | 150 | 148 |
| Not completed | 12 | 7 | 8 |
| Withdrew: Adverse event | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 5 | 5 |
| Withdrew: Left after installation | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 |
| Withdrew: Prohibited medication used during study participation | 0 | 1 | 0 |
Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision on Day 1
| percentage of participants | Aceclidine + Brimonidine (LNZ101) | Aceclidine Ophthalmic Solution (LNZ100) | Brimonidine Ophthalmic Solution |
|---|---|---|---|
| Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision | 48.68 (40.823 to 56.547) | 64.5 (57.076 to 71.920) | 11.49 (6.515 to 16.464) |
Collected over 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aceclidine + Brimonidine (LNZ101) | 0/156 (0%) | 3/156 (1.9%) | 73/156 (46.8%) |
| Aceclidine Ophthalmic Solution (LNZ100) | 0/157 (0%) | 0/157 (0%) | 53/157 (33.8%) |
| Brimonidine Ophthalmic Solution | 0/156 (0%) | 0/156 (0%) | 25/156 (16%) |
| Event | Aceclidine + Brimonidine (LNZ101) | Aceclidine Ophthalmic Solution (LNZ100) | Brimonidine Ophthalmic Solution |
|---|---|---|---|
| Ocular Treatment-Emergent Serious Adverse EventsEye disorders | 1/156 | 0/157 | 0/156 |
| Non-Ocular Treatment-Emergent Serious Adverse EventInjury, poisoning and procedural complications | 1/156 | 0/157 | 0/156 |
| Non-Ocular Treatment-Emergent Serious Adverse EventMusculoskeletal and connective tissue disorders | 1/156 | 0/157 | 0/156 |
| Event | Aceclidine + Brimonidine (LNZ101) | Aceclidine Ophthalmic Solution (LNZ100) | Brimonidine Ophthalmic Solution |
|---|---|---|---|
| Instillation Site IrritationGeneral disorders | 31/156 | 30/157 | 10/156 |
| Visual ImpairmentEye disorders | 28/156 | 16/157 | 0/156 |
| Vision blurredEye disorders | 6/156 | 5/157 | 15/156 |
| Ocular HyperaemiaEye disorders | 8/156 | 7/157 | 0/156 |
| Age, Continuous(years) | Aceclidine + Brimonidine (LNZ101) | Aceclidine Ophthalmic Solution (LNZ100) | Brimonidine Ophthalmic Solution | Total |
|---|---|---|---|---|
| Mean | 56.2 ± 6.55 | 55.3 ± 6.07 | 54.9 ± 6.45 | 55.5 ± 6.37 |
| Sex: Female, Male(Participants) | Aceclidine + Brimonidine (LNZ101) | Aceclidine Ophthalmic Solution (LNZ100) | Brimonidine Ophthalmic Solution | Total |
|---|---|---|---|---|
| Female | 99 | 109 | 99 | 307 |
| Male | 57 | 48 | 57 | 162 |
| Ethnicity (NIH/OMB)(Participants) | Aceclidine + Brimonidine (LNZ101) | Aceclidine Ophthalmic Solution (LNZ100) | Brimonidine Ophthalmic Solution | Total |
|---|---|---|---|---|
| Hispanic or Latino | 55 | 36 | 47 | 138 |
| Not Hispanic or Latino | 101 | 121 | 109 | 331 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Aceclidine + Brimonidine (LNZ101) | Aceclidine Ophthalmic Solution (LNZ100) | Brimonidine Ophthalmic Solution | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 1 | 3 |
| Asian | 7 | 10 | 8 | 25 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 12 | 6 | 10 | 28 |
| White | 134 | 138 | 135 | 407 |
| More than one race | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 2 | 1 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2022 to primary completion in Dec 2023, 11 months.
Results were first posted in Feb 2026, 2 years 2 months after primary completion. A results delay was requested in Dec 2024.
Of 19 phase 3 interventional studies under Presbyopia, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 11. This study's 11 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aceclidine · Brimonidine
LENZ Therapeutics, Inc